Payment overview · 2025
General Payments
$1,605.66
80 reported records · 13 companies
Healthcare provider profile · identity verified
Robert Leon Lynch, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · RIVERBANK, CA · NPI 1184644031
Verified facts
What the public records show
CMS Open Payments records show Robert Leon Lynch, M.D. received $1,605.66 in general payments during 2025 across 80 reported records.
AstraZeneca Pharmaceuticals LP accounted for 40.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Rexulti, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 246 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 246 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $648.17 | 40.4% | 10 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $208.17 | 13.0% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $193.34 | 12.0% | 22 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $143.56 | 8.9% | 14 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $116.39 | 7.2% | 9 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $90.60 | 5.6% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $64.15 | 4.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.96 | 2.0% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $29.88 | 1.9% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $24.65 | 1.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.92 | 1.4% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.20 | 1.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.67 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,605.66 | 80 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $616.10 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $405.81 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $401.66 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $208.17 | 11 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $172.34 | 21 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $172.34 | 21 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $143.56 | 14 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $116.39 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $90.60 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $64.15 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $29.88 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $24.65 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $22.92 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 187 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 73 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 246 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 59 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
73 | 16 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
246 | 67 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
187 | 48 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
59 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
246 | 67 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
187 | 48 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
28 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1197 | 361 |
| Levothyroxine Sodium | Levothyroxine Sodium | 790 | 212 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 654 | 90 |
| Lisinopril | Lisinopril | 570 | 179 |
| Alprazolam | Alprazolam | 556 | 98 |
| Omeprazole | Omeprazole | 460 | 146 |
| Metoprolol Succinate | Metoprolol Succinate | 413 | 128 |
| Amlodipine Besylate | Amlodipine Besylate | 406 | 124 |
| Hydrochlorothiazide | Hydrochlorothiazide | 389 | 116 |
| Metformin Hcl | Metformin Hcl | 385 | 123 |
| Valsartan | Valsartan | 374 | 109 |
| Furosemide | Furosemide | 343 | 113 |
| Gabapentin | Gabapentin | 325 | 94 |
| Tamsulosin Hcl | Tamsulosin Hcl | 273 | 96 |
| Losartan Potassium | Losartan Potassium | 263 | 84 |
| Potassium Chloride | Potassium Chloride | 259 | 87 |
| Jardiance | Empagliflozin | 246 | 67 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 244 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 240 | 78 |
| Ezetimibe | Ezetimibe | 216 | 69 |
| Tramadol Hcl | Tramadol Hcl | 211 | 57 |
| Simvastatin | Simvastatin | 208 | 57 |
| Eliquis | Apixaban | 187 | 48 |
| Glipizide | Glipizide | 182 | 60 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 177 | 135 |
| Carvedilol | Carvedilol | 144 | 45 |
| Fenofibrate | Fenofibrate | 142 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 141 | 34 |
| Alendronate Sodium | Alendronate Sodium | 138 | 45 |
| Fluoxetine Hcl | Fluoxetine Hcl | 126 | 36 |
| Donepezil Hcl | Donepezil Hcl | 125 | 31 |
| Azithromycin | Azithromycin | 123 | 89 |
| Memantine Hcl | Memantine Hcl | 121 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 117 | 20 |
| Prednisone | Prednisone | 115 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 36 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 106 | 54 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 104 | 74 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 102 | 54 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 102 | 71 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 95 | 24 |
| Allopurinol | Allopurinol | 92 | 24 |
| Finasteride | Finasteride | 92 | 32 |
| Temazepam | Temazepam | 91 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 90 | 29 |
| Lorazepam | Lorazepam | 88 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 86 | 28 |
| Sertraline Hcl | Sertraline Hcl | 85 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 84 | 24 |
| Ondansetron Odt | Ondansetron | 80 | 33 |
| Trazodone Hcl | Trazodone Hcl | 74 | 21 |
| Farxiga | Dapagliflozin Propanediol | 73 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 72 | 24 |
| Ozempic | Semaglutide | 71 | 16 |
| Atenolol | Atenolol | 70 | 22 |
| Naproxen | Naproxen | 70 | 27 |
| Montelukast Sodium | Montelukast Sodium | 67 | 26 |
| Buspirone Hcl | Buspirone Hcl | 66 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 59 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 14 |
| Baclofen | Baclofen | 58 | 22 |
| Lovastatin | Lovastatin | 58 | 17 |
| Spironolactone | Spironolactone | 58 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 15 |
| Famotidine | Famotidine | 54 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 15 |
| Estradiol | Estradiol | 51 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 14 |
| Bupropion Xl | Bupropion Hcl | 49 | 15 |
| Clonidine Hcl | Clonidine Hcl | 49 | 15 |
| Meloxicam | Meloxicam | 48 | 15 |
| Myrbetriq | Mirabegron | 48 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 47 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 18 |
| Ketoconazole | Ketoconazole | 46 | 19 |
| Glimepiride | Glimepiride | 45 | 14 |
| Aripiprazole | Aripiprazole | 44 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 15 |
| Ibuprofen | Ibuprofen | 44 | suppressed |
| Clonazepam | Clonazepam | 42 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 42 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | 12 |
| Pregabalin | Pregabalin | 41 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 41 | suppressed |
| Klor-Con 10 | Potassium Chloride | 40 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 30 |
| Xarelto | Rivaroxaban | 38 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 35 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 35 | suppressed |
| Amoxicillin | Amoxicillin | 34 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Fluconazole | Fluconazole | 34 | 23 |
| Mirtazapine | Mirtazapine | 34 | 11 |
| Glyburide | Glyburide | 33 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | 12 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 32 | 26 |
| Ventolin Hfa | Albuterol Sulfate | 31 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 30 | 17 |
| Rybelsus | Semaglutide | 29 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 23 |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 26 |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 27 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 27 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 27 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | 16 |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Fentanyl | Fentanyl | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Methadone Hcl | Methadone Hcl | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Carisoprodol | Carisoprodol | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Rexulti | Brexpiprazole | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | 11 |
| Digoxin | Digoxin | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 15 |
| Qvar Redihaler | Beclomethasone Dipropionate | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Benzonatate | Benzonatate | 16 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Prolia | Denosumab | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,605.66 · 80 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FARXIGA, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, NUZYRA, PREVNAR 20, REXULTI, TRELEGY ELLIPTA, XIFAXAN, ZAVZPRET | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error